From the Guidelines
Human chorionic gonadotropin (hCG) does not directly cause polycythemia in patients on testosterone replacement therapy (TRT), and its use may help mitigate this risk by promoting more physiologic testosterone production. Polycythemia, characterized by elevated red blood cell counts, is a known side effect of exogenous testosterone therapy, occurring in approximately 5-20% of TRT patients 1, 2. The mechanism of testosterone-induced polycythemia is related to the stimulation of erythropoiesis, and the risk varies with the dosage and form of testosterone used, with injectable forms potentially carrying a higher risk 1.
Key Considerations
- hCG works by stimulating the testes to produce testosterone naturally, which can lead to more balanced and physiologic hormone levels compared to exogenous testosterone supplementation alone.
- When used alongside TRT, hCG at doses of 500-1500 IU administered 2-3 times weekly can help maintain testicular function while potentially reducing the risk of polycythemia.
- Patients on TRT, regardless of whether hCG is part of their regimen, should undergo regular hematocrit monitoring, with levels above 54% typically requiring intervention such as therapeutic phlebotomy or medication adjustment 2.
- The incidence of polycythemia can vary based on the modality of testosterone therapy, with injectable testosterone associated with greater treatment-induced increases in hemoglobin and hematocrit 2.
Monitoring and Management
- Baseline measurement of hemoglobin/hematocrit is recommended before commencing testosterone therapy, and if the hematocrit exceeds 50%, the etiology should be investigated before proceeding with therapy 2.
- Regular monitoring of hematocrit levels during TRT is crucial, with interventions considered for levels above 54% to prevent complications associated with polycythemia.
From the Research
Polycythemia and hCG in TRT
- Polycythemia is a condition characterized by an increased concentration of red blood cells, which can be a concern in patients undergoing testosterone replacement therapy (TRT) 3.
- Human chorionic gonadotropin (hCG) is sometimes used in conjunction with TRT to stimulate testicular growth and spermatogenesis, particularly in patients with hypogonadotropic hypogonadism who desire fertility 4, 5.
- However, the effect of hCG on polycythemia in patients on TRT is not explicitly stated in the provided studies.
hCG and Hematocrit Levels
- One study found that weekly treatment with hCG did not change hematocrit levels in patients with testosterone levels above 300 ng/dL 6.
- This suggests that hCG may not contribute to the development of polycythemia in these patients, but more research is needed to confirm this finding.
TRT and Polycythemia
- TRT has been associated with an increased risk of polycythemia, particularly in older men with a history of heart failure 3.
- However, the provided studies do not specifically address the relationship between hCG and polycythemia in patients on TRT.